Title: A single-arm, open-label, phase II trial of entrectinib in patients with advanced tumours harbouring NTRK fusions or ROS1 gene rearrangements detected by comprehensive genomic profiling.
The aim of this ASPiRATION and MoST substudy to assess the clinical activity of entrectinib in adult patients with advanced cancers harbouring NTRK or ROS1 gene alterations.
Adult patients with advanced cancers harbouring NTRK fusions or ROS1 gene rearrangements. NSCLC patients with ROS1 gene alterations must be FISH-negative, i.e. not eligible for reimbursed ROS1-targeted treatment.
Dr Peey-Sei Kok, A/Prof Tom John, and Dr Subotheni Thavaneswaran